GlassScriptPhysician profile
Alexander Pena
NPI 1477937936
$9,094.94
in general payments reported to CMS, 2019-2025
40 companies · $1,223 in 2025
The $1,223 reported for 2025 was more than what 83% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,985 · 2022: $2,187 · 2023: $1,389 · 2024: $1,311 · 2025: $1,223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,874 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,873.67 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,570.87 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,335.23 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $1,182.24 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $1,079.66 | 2021-2025 | Evenity, Repatha, Otezla |
| Lilly USA, LLC | $360.63 | 2021-2025 | Kisunla, Jardiance, Zepbound |
| Biohaven Pharmaceuticals, INC. | $264.75 | 2021 | |
| Sanofi-Aventis U.S. LLC | $250.83 | 2021-2022 | |
| Antares Pharma, INC. | $238.03 | 2023-2025 | Xyosted, Nocdurna, Tlando |
| Pfizer INC. | $236.54 | 2021-2025 | |
| Abbott Laboratories | $207.56 | 2021-2023 | Freestyle Libre 3 |
| Idorsia Pharmaceuticals US INC | $184.17 | 2022-2024 | Quviviq |
| Neurocrine Biosciences, INC. | $176.49 | 2022 | |
| Corcept Therapeutics | $155.68 | 2021 | |
| Daiichi Sankyo INC. | $138.24 | 2021-2023 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $134.35 | 2023-2025 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Pena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.